A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)
Phase of Trial: Phase IV
Latest Information Update: 17 Jul 2018
Price : $35 *
At a glance
- Drugs Mirabegron (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms MAESTRO
- 09 Jul 2018 Status changed from recruiting to completed.
- 11 Jul 2017 Planned End Date changed from 1 May 2017 to 1 May 2018.
- 11 Jul 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.